, Volume 69, Issue 1–2, pp 51–57 | Cite as

Chemical Fingerprinting and Hierarchical Clustering Analysis of Centella asiatica from Different Locations in China

  • Xiao-Gang Zhang
  • Ting Han
  • Qiao-Yan Zhang
  • Hong Zhang
  • Bao-Kang Huang
  • Li-Li Xu
  • Lu-Ping Qin


Centella asiatica (L.) Urban is a widely distributed herbaceous plant with great medicinal value that has been extensively used in traditional Chinese medicine. For effective quality control of C. asiatica, a feasible approach and control system is necessary. In this paper, a chemical fingerprint method (column liquid chromatography) was developed for investigating and demonstrating the variance of chemical components among different populations of C. asiatica, from 14 locations in China. The LC data showed considerable variation of chemical constituents among C. asiatica populations. Four chemotypes were visually developed from the chromatographic profiles. The hierarchical clustering analysis further suggested that the samples were divided into four major groups. The grouping of 14 C. asiatica populations in hierarchical clustering analysis was in good agreement with the visual comparison of their chromatograms, as demonstrated by chemotypes. In addition, the bioactive compound asiaticoside in this herb was quantitatively determined by a validated reversed-phase liquid chromatography analysis. Chemotype I was identified as asiaticoside-rich chemotype and exhibited significantly higher amounts of asiaticoside. These findings and results provide a solid basis to establish good agriculture practice and select geo-authentic crude drug for C. asiatica. The established method was considered to be suitable for fingerprint analysis for the quality control of C. asiatica.


Column liquid chromatography Chemical fingerprint Hierarchical clustering analysis Asiaticoside Centella asiatica 



This work was supported by the National Natural Science Foundation of China (no. 30572327). We thank Dr. C. J. Zheng, School of Pharmacy, Second Military Medical University, China, for technical assistance.


  1. 1.
    Normile D (2003) Science 299:188–190CrossRefGoogle Scholar
  2. 2.
    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998) JAMA 280:1569–1575CrossRefGoogle Scholar
  3. 3.
    Chevallier A, Namba T (2000) The encyclopedia of medicinal plants. Seibundo Shinkosha Publishing Co. Ltd, China, p 74Google Scholar
  4. 4.
    Joshi SG (2000) Medicinal plants. Oxford & IBH Publishing Co. Pvt Ltd, New Delhi, p 31Google Scholar
  5. 5.
    Gupta R, Flora SJS (2006) J Appl Toxicol 26:213–222CrossRefGoogle Scholar
  6. 6.
    Punuree K, Wild CP, Kasinrerk W, Vinitketkumnuen U (2005) Asian Pac J Cancer Prev 6:396–400Google Scholar
  7. 7.
    Subban R, Veerakumar A, Manimaran R, Hashim KM, Balachandran I (2008) J Nat Med 62:369–373CrossRefGoogle Scholar
  8. 8.
    Yoshida M, Fuchigami M, Nagao T, Okabe H, Matsunaga K, Takata J, Karube Y, Tsuchihashi R, Kinjo J, Mihashi K, Fujioka T (2005) Biol Pharm Bull 28(1):173–175CrossRefGoogle Scholar
  9. 9.
    Park BC, Bosire KO, Lee ES, Lee YS, Kim JA (2005) Cancer Lett 218:81–90CrossRefGoogle Scholar
  10. 10.
    European Pharmacopoeia (2002) 4th ednGoogle Scholar
  11. 11.
    Sampson JH, Raman A, Karlsen G, Navsaria H, Leigh IM (2001) Phytomedicine 8(3):230–235CrossRefGoogle Scholar
  12. 12.
    Shukla A, Rasik AM, Dhawan DN (1999) Phytother Res 13:50–54CrossRefGoogle Scholar
  13. 13.
    Lu L, Ying K, Wei SM, Fang Y, Liu YL, Lin HF, Ma L, Mao YM (2004) Int J Dermatol 43:801–807CrossRefGoogle Scholar
  14. 14.
    Das A, Mallick R (1991) Bot Bull Acad Sin 32:1–8Google Scholar
  15. 15.
    Randriamampionona D, Diallo B, Rakotoniriana F, Rabemanantsoa C, Cheuk K, Corbisier AM, Mahillon J, Ratsimamanga S, Jaziri ME (2007) Fitoterapia 78:482–489CrossRefGoogle Scholar
  16. 16.
    WHO (2000) General guidelines for methodologies on research and evaluation of traditional medicine. WHO, Geneva, p 1Google Scholar
  17. 17.
    FDA (2000) Guidance for industry-botanical drug products (draft guidance) FDA, Washington, DC, I, B, 2e; 3eGoogle Scholar
  18. 18.
    EMA (2001) Note for guidance on quality of herbal medicinal products European Medicines Agency, London, p 6Google Scholar
  19. 19.
    SFDA. State Drug Administration of China (2000) Requirements for studying fingerprint of traditional Chinese medicine injection (Draft). Chin Tradition Patent Med 22:671–675Google Scholar
  20. 20.
    Liang YZ, Xie P, Chan K (2004) J Chromatogr B 812:53–70Google Scholar
  21. 21.
    Schaneberg BT, Mikell JR, Bedir E, Khan IA (2003) Pharmazie 58:381–384Google Scholar
  22. 22.
    Pan J, Kai GQ, Yuan CX, Zhou BB, Jin RS, Yuan Y (2007) Chin J Chromatogr 25(3):316–318CrossRefGoogle Scholar

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2008

Authors and Affiliations

  • Xiao-Gang Zhang
    • 1
  • Ting Han
    • 1
  • Qiao-Yan Zhang
    • 1
  • Hong Zhang
    • 1
  • Bao-Kang Huang
    • 1
  • Li-Li Xu
    • 1
  • Lu-Ping Qin
    • 1
  1. 1.Department of Pharmacognosy, School of PharmacySecond Military Medical UniversityShanghaiPeople’s Republic of China

Personalised recommendations